Summary
Dr Reddy's Laboratories CEO Erez Israeli stated that increased US tariffs on generic medicines will lead to higher drug prices in India. He noted that relocating manufacturing to the US is impractical and the company will monitor the situation, anticipating additional costs due to the proposed tariff changes.